In the latest trading session, 1.24 million Anavex Life Sciences Corporation (NASDAQ:AVXL) shares changed hands as the company’s beta touched 0.71. With the company’s most recent per share price at $12.20 changing hands around $1.02 or 9.12% at last look, the market valuation stands at $1.03B. AVXL’s last price was a premium, traded about 5.74% off its 52-week high of $11.50. The share price had its 52-week low at $3.25, which suggests the last value was 73.36% up since then. When we look at Anavex Life Sciences Corporation’s average trading volume, we note the 10-day average is 1.91 million shares, with the 3-month average coming to 1.30 million.
Analysts gave the Anavex Life Sciences Corporation (AVXL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AVXL as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Anavex Life Sciences Corporation’s EPS for the current quarter is expected to be -0.19.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Anavex Life Sciences Corporation (NASDAQ:AVXL) trade information
Instantly AVXL is in green as seen in intraday trades today. With action 32.46%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 31.04%, with the 5-day performance at 32.46% in the green. However, in the 30-day time frame, Anavex Life Sciences Corporation (NASDAQ:AVXL) is 33.92% up. Looking at the short shares, we see there were 19.69 million shares sold at short interest cover period of 10.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need a downside of -10.91% from its recent market value. According to analyst projections, AVXL’s forecast low is 11 with 11 as the target high. To hit the forecast high, the stock’s price needs a 9.84% surge from its current level, while the stock would need to tank 9.84% for it to hit the projected low.
Anavex Life Sciences Corporation (AVXL) estimates and forecasts
Data shows that the Anavex Life Sciences Corporation share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 219.37% over the past 6 months, a -53.85% in annual growth rate that is considerably lower than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%. Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -9.03%.
Anavex Life Sciences Corporation (NASDAQ:AVXL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.05% of Anavex Life Sciences Corporation shares while 32.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 33.04%. There are 32.04% institutions holding the Anavex Life Sciences Corporation stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.7506% of the shares, roughly 6.39 million AVXL shares worth $26.97 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.5154% or 4.55 million shares worth $19.19 million as of 2024-06-30.
